Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Stockholders Equity of $602.69 million for fiscal year 2025.
MADRIGAL PHARMACEUTICALS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $602.69M | -20.1% |
| 2024 | $754.38M | +86.1% |
| 2023 | $405.33M | +105.3% |
| 2022 | $197.39M | +0.7% |
| 2021 | $196.11M | -18.3% |
| 2020 | $239.97M | -42.4% |
| 2019 | $416.56M | -12.7% |
| 2018 | $476.98M | +161.7% |
| 2017 | $182.26M | +400.6% |
| 2016 | $36.41M | +174.4% |
| 2015 | -$48.91M | -16.3% |
| 2014 | -$42.07M | -185.7% |
| 2013 | $49.09M | -34.6% |
| 2012 | $75.07M | +408.1% |
| 2011 | $14.77M | -37.1% |
| 2010 | $23.48M | -5.7% |
| 2009 | $24.91M | +142.4% |
| 2008 | -$58.79M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $625.73M | -19.5% | -10.1% |
| June 30, 2025 | $695.98M | -18.8% | -2.1% |
| March 31, 2025 | $710.64M | -16.5% | -5.8% |
| December 31, 2024 | $754.38M | +86.1% | -2.9% |
| September 30, 2024 | $777.15M | +3393.0% | -9.3% |
| June 30, 2024 | $857.12M | +728.1% | +0.7% |
| March 31, 2024 | $850.76M | +466.7% | +109.9% |
| December 31, 2023 | $405.33M | +105.3% | +1721.8% |
- MADRIGAL PHARMACEUTICALS, INC. showed a decrease of -20.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, MADRIGAL PHARMACEUTICALS, INC.’s stockholders equity has grown by 1125.1% (from -$58.79 million to $602.69 million).
- The most recent figure is from MADRIGAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: